TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02181634
Drug: Nab-Paclitaxel and Gemcitabine
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-Paclitaxel will be administered first, at a dose of 125 mg/m² IV over a period of 30 minutes; gemcitabine will be administered second, at a dose of 1000 mg/m² over a period of 30 minutes.
Study: NCT03611595
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles
Study: NCT03611595
Drug: 13-cis-retinoic acid
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
Study: NCT01440608
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pill form, to be given once, 200 mg dosage for children 1-2 years of age, 400 mg dosage for children 2-3 years of age
Study: NCT01102608
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks
Study: NCT03140813
Drug: AZD7325 (Low-Dose)
Normalized name: ethinyl estradiol
DrugBank: AZD-7325 (DB13994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg PO BID
Study: NCT02537015
Drug: Bimatoprost
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
Study: NCT02103673
Drug: DAOIB
Normalized name: Dapagliflozin and Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intervention drug: DAOIB. Dosage: 250-1500 mg/day by mouth. Duration: 6 weeks
Study: NCT02832362
Drug: Carbomer 980
Normalized name: Carbomer 980
DrugBank: Carbomer homopolymer type C (DB14091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product containing 0.5% carbomer 980 gel
Study: NCT03696459
Drug: JNJ-53718678 500 mg
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered JNJ-53718678, 500 mg as oral suspension in Part 2.
Study: NCT03696459
Drug: Moxifloxacin 400 mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be administered moxifloxacin 400 mg as capsule in Part 2.
Study: NCT03696459
Drug: Moxifloxacin Placebo
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be administered moxifloxacin matching placebo in Part 2.
Study: NCT01006291
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted.
Study: NCT01006291
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected s.c. (under the skin) once daily. Dose was individually adjusted.
Study: NCT01006291
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.
Study: NCT00702715
Drug: sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each subject will receive an~intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After~this dose, maintenance doses of 0.1 - 0.2 mg.kg-1~rocuronium may be given. In case of maintenance dosing, the target depth of~neuromuscular blockade has to be maintained at 1-2 post-tetanic counts (PTC). After the last dose of rocuronium has been administered, the subject will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC.
Study: NCT01574183
Drug: Vilazodone
Normalized name: Vilazodone
DrugBank: Vilazodone (DB06684)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: up to 40 mg capsule daily
Study: NCT02185859
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The lidocaine group (Group L)- 1% lidocaine 40 mL is prepared in a 50 mL syringe; A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. (Group L subjects are administered lidocaine 2 mg/kg for 15 minutes immediately after the anesthesia induction, and then lidocaine 2 mg/kg/h is continuously injected. The dose of lidocaine and magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.)
Study: NCT02185859
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the magnesium group (Group M)- MgSO4 4g 40 mL is prepared in a 50 mL syringe.) A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. The dose of magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.
Study: NCT02185859
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the control group (Group C) - 0.9% normal saline 40 mL is prepared in a 50 cc syringe. A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room.Group C subjects are administered the same dose of normal saline.
Study: NCT04150913
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous, dosage per protocol. Day 0 through Day 6.
Study: NCT04150913
Drug: Axicabtagene Ciloleucel
Normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once, intravenous infusion, dosage per protocol
Study: NCT01971099
Drug: tribulus terrestris
Normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will use 750mg/day of tribulus terrestris
Study: NCT02602470
Drug: Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser \& Moisturizing
Study: NCT02602470
Drug: Azelaic Acid Cream
Normalized name: Azelaic Acid
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelaic Acid Cream 20%
Study: NCT02482818
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Increasing dose regimen depending on tolerability followed by decreasing dose regimen.
Study: NCT04884464
Drug: Chlorhexidine Gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage: application of an even coat of 1mm thickness Frequency: 3 times/day (after main meals) Duration: 2 weeks
Study: NCT02712047
Drug: Fluticasone furoate (FF) (100 mcg)
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: First blister strip contains FF blended with lactose, 100 mcg per blister
Study: NCT02712047
Drug: Vilanterol (VI) (25 mcg)
Normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second blister strip contains vilanterol blended with lactose and magnesium stearate, 25 mcg per blister
Study: NCT00826462
Drug: triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection with triamcinolone 10 mg at start and at 3 weeks
Study: NCT02602470
Drug: Metronidazole gel
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser
Study: NCT02602470
Drug: Metronidazole cream
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser
Study: NCT00826462
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg of lidocaine at start and at 3 weeks
Study: NCT01145677
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 100-300 mg/day orally twice per day
Study: NCT02602470
Drug: Metronidazole Emulsion
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole Emulsion 0.75%
Study: NCT02602470
Drug: Metronidazole Lotion
Normalized name: metronidazole Topical Lotion
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole Lotion 0,75%
Study: NCT02602470
Drug: Brimonidine Tartrate Gel
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine Tartrate Gel 0.33%
Study: NCT02145949
Drug: Essential Amino Acids (EAA)
Normalized name: silk amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily ingestion of 20 or 23 grams of EAA for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
Study: NCT02989259
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apatinib 500mg p.o. qd
Study: NCT00003518
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01578109
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01578109
Drug: Sorafenib Tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00153751
Drug: Traditional Chinese Medicine
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
DrugBank: Borneol (DB11288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: They are Common peony root, Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Curcumae Longae, Fructus Schisandrae Chinensis, Pericarpium Citri Reticulatae, and Rhizoma Corydalis Yanhusuo.
Study: NCT00403611
Drug: Praziquantel 60 mg/kg
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel (Distocide) 60 mg/kg single oral dose
Study: NCT00403611
Drug: Praziquantel 40 mg/kg
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel (Distocide) 40 mg/kg single oral dose
Study: NCT00003518
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00436345
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conventional sedation in medical and post-surgical Intensive Care Unit subjects requiring mechanical
Study: NCT02415036
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03609606
Drug: D013
Normalized name: MGD013 dual-affinity re-targeting (DART)
DrugBank: Tebotelimab (DB16685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral administration of 1 tablet under fasting conditions for 7 days
Study: NCT03609606
Drug: D326 and D337
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
Study: NCT04222010
Drug: loco-regional anesthesia serratus plane bloc (Ropivacaine 2 mg/mL, 40 mL) and paravertebral placebo bloc (saline, 20 mL)
Normalized name: Gold-Bloc
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia
Study: NCT02467686
Drug: Cimicifuga racemosa
Normalized name: CIMICIFUGA RACEMOSA ROOT
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Cimicifuga racemosa effects on the sexuality of women with Breast cancer
Study: NCT02467686
Drug: tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen
Study: NCT02467686
Drug: exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.
Study: NCT02016027
Drug: Carica folia
Normalized name: Carica papaya preparation
DrugBank: Papaya (DB10658)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00103376
Drug: Velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part A: 1.3 mg/m2 administered on days 1, 4, 8 and 11 followed by 10 days rest. A second cycle will be given at the same schedule. Cycle 3 will include 3 weekly injections.~Part B: 1.3mg/m2 administered weekly for 3 weeks followed by 1 week break
Study: NCT00103376
Drug: LH-RH Agonist
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: given as a 3 month depo-injection
Study: NCT03482960
Drug: Hyperpolarized Xenon gas
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperpolarized Xenon gas~* Hyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen)~* Administration: By mouthpiece attached to a single use Tedlar bag.~* Dosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe.~* Frequency: 10-minute interval between doses.
Study: NCT03482960
Drug: PFP
Normalized name: PFPE - Perfluoroalkylpolyether
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred.
Study: NCT04726631
Drug: Basal insulin analogue
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Analogue insulin is a sub-group of human insulin
Study: NCT04726631
Drug: Neutral Protamine Hagedorn
Normalized name: Neutral protamine hagedorn insulin
DrugBank: Neutral Protamine Hagedorn (NPH) insulin (DB18001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: is an intermediate-acting insulin
Study: NCT00536991
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01296672
Drug: Finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finasteride 5mg every day by mouth for 3 months
Study: NCT01568255
Drug: Ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergocalciferol therapy at 50,000IU for 8 weeks
Study: NCT00018343
Drug: estrogen
Normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00887965
Drug: Previous denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
Study: NCT00518531
Drug: alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.
Study: NCT00518531
Drug: denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.
Study: NCT00993525
Drug: Intravitreal injection of ranibizumab
Normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography
Study: NCT00032825
Drug: Ketaconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00032825
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00219024
Drug: aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00093379
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/m\^2 by vein (IV) over 2 hours on days 1, 8, 22, and 29.
Study: NCT00003560
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003560
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01503502
Drug: flumatinib
Normalized name: Flumatinib
DrugBank: Flumatinib (DB11904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.
Study: NCT01503502
Drug: imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib was supplied as 100 mg film-coated tablets. Storage condition: 25°C (77°F). Protected from moisture.
Study: NCT02843490
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Three injections (o.5 mg Ranibizumab) within the first three months is followed by an individual therapy interval based on the clinical progress (PRN)
Study: NCT01338454
Drug: transamin
Normalized name: Transamine
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TA was administered intravenously over a 5 min period at delivery of the anterior shoulder
Study: NCT04050280
Drug: Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Induction:~G-CSF 300 mcg subcutaneously daily on days 0-5.~Cladribine 5 mg/m2 in normal saline given intravenously over 2 hours daily on days 1-5.~Cytarabine 2000 mg/m2 in normal saline given intravenously over 4 hours daily on days 1-5.~Gemtuzumab ozogamicin 3 mg/m2 intravenously over 2 hours on days 1 and 4, prior to cladribine and cytarabine.~Consolidation:~If CRMRD-, CR or CRi is confirmed by bone marrow biopsy and aspirate after induction chemotherapy, patients may receive one cycle of consolidation chemotherapy (at the discretion of the investigator) with the same CLAG-GO regimen at the same doses given for induction. In addition, the investigator has the option of giving CLAG alone without GO if there is concern for increased risk of sinusoidal obstruction syndrome.~Patients who remain in CRMRD-, CR or CRi after consolidation chemotherapy may receive up to eight infusions of GO 2 mg/m2 approximately every 28 days.
Study: NCT01227135
Drug: hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01227135
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01652469
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150 mg/day p.o. continuously with 21 days cycle.
Study: NCT01652469
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 as an IV infusion every 21 days.
Study: NCT00133003
Drug: Abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute \[maximum, 10 microg/min\] infusion for 12 hours, plus heparin, 70 U/kg of body weight
Study: NCT00257257
Drug: Rimonabant (SR141716)
Normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT02223377
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1st dose: syringe of 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents is administered. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)